On October 14, 2026 Caris Life Sciences (NASDAQ: CAI), a leading TechBio company, reported that researchers from Caris and the Caris Precision Oncology Alliance (Caris POA) will present eight posters at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The research showcases the expanding impact of artificial intelligence, molecular profiling and multimodal data integration in advancing precision oncology across multiple tumor types.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The two Caris-led posters focus on AI-driven treatment prediction and risk stratification in breast cancer, as well as six collaborative investigations conducted with members of the Caris POA. Together, the posters span breast, lung, endometrial, melanoma and immuno-oncology research and demonstrate how comprehensive molecular and clinico-genomic data can reveal novel biological insights and inform more personalized treatment approaches.

"Artificial intelligence is transforming our ability to understand cancer biology and predict therapeutic response on an unprecedented scale," said James Hamrick MD, MPH, Chairman of the Caris POA. "The posters to be presented at ESMO (Free ESMO Whitepaper) 2026 highlight how the integration of AI, molecular profiling and real-world clinical data can uncover clinically meaningful insights that ultimately help guide more precise treatment decisions for patients."

Caris-Led Studies

Posters:
178P – Caris CapeAI, An Artificial Intelligence Model of ER+ Breast Cancer Response to Capecitabine
Authors: Javier Pascual Lopez, Chen Sun, Miguel J. Gil, et al.
Session: AI for clinical workflows and decision-making
Date and time: Sunday, 25 October 2026, 12:00–12:45 (Madrid time)

217P – Toward Precision Extended Endocrine Therapy in Early HR+ Breast Cancer: Multimodal AI for Risk and Benefit Stratification
Authors: Eleftherios P. Mamounas, Md Ashequr Rahman, Ming Chen, et al.
Session: AI for clinical workflows and decision-making
Date and time: Sunday, 25 October 2026, 12:00–12:45 (Madrid time)

Caris Precision Oncology Alliance Collaborative Studies

Posters:
3285P – Characterization of G-protein coupled estrogen receptor (GPER) and estrogen receptor in EGFR-mutated NSCLC leading to survival differences
Authors: Robert Hsu, Mercy Kehinde-Ige, Sharon Wu, et al.
Session: Pathology and molecular pathology
Date and time: Friday, 23 October 2026, 15:15–16:00 (Madrid time)

1296P – Genomic Scar–Defined Homologous Recombination Deficiency (HRD) and Tumor Immune Microenvironment in Endometrial Cancer (EC)
Authors: Hiromichi Nakajima, Kenichi Harano, Sharon Wu, et al.
Session: Gynecological cancers
Date and time: Monday, 26 October 2026, 12:00–12:45 (Madrid time)

4395P – A 25-gene T-cell exhaustion signature refines TLS-based prediction of immunotherapy benefit
Authors: Nathan El Ghazzi, Andrew Elliott, George Sledge, et al.
Session: Translational research and biomarkers
Date and time: Friday, 23 October 2026, 15:15–16:00 (Madrid time)

2136P – Site-dependent stromal-mesenchymal reprogramming associated with survival and immunotherapy outcomes in BAP1-mutant uveal melanoma (UM)
Authors: Clara J. Oh, Jingshu Chen, Nishant Gandhi, et al.
Session: Melanoma
Date and time: Saturday, 24 October 2026, 12:00–12:45 (Madrid time)

2681P – Characterization of differences across Organ Site Specific Metastasis in NSCLC by Race/Ethnicity
Authors: Robert Hsu, Nishant Gandhi, Krithika Chennapan, et al.
Session: NSCLC, metastatic
Date and time: Monday, 26 October 2026, 12:00–12:45 (Madrid time)

2686P – RRAS2mt Non-small cell lung cancer (NSCLC) defines a distinct subset of RASmt NSCLC
Authors: Sharon Wu, Hui Jing Hoe, Eleonora Gariazzo, et al.
Session: NSCLC, metastatic
Date and time: Monday, 26 October 2026, 12:00–12:45 (Madrid time)

Research highlights will be available at the Caris booth #1021.

(Press release, Caris Life Sciences, OCT 14, 2026, View Source [SID1234673462])